Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab-Phase I Trial in Indolent B-cell Lymphoma

Inclusion Criteria:

Histologically confirmed indolent B-cell non-Hodgkin lymphoma.
Radiological measurable disease.
Previous treatment for lymphoma is allowed, with the exception of use of bendamustine within 6 months or any prior use of vincristine sulfate liposome injection
Eastern Cooperative Oncology Group performance status 0 or 1;
Life expectancy of at least 6 months;
Adequate organ and marrow function;
Women of child-bearing potential and men must agree to use adequate contraception.
Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

History of allergic reactions attributed to any drug used in the study.
Any lymphoma-directed therapy within 4 weeks.
Any prior treatment with vincristine sulfate liposome injection.
Prior treatment with bendamustine or vincristine sulfate within 180 days of enrollment.
Patients who are receiving any other investigational agents with the exception of endocrine therapy for breast or prostate cancer.
Central nervous system involvement.
Peripheral sensory or motor neuropathy.
History of a demyelinating condition.
Positive test for the Human Anti-Chimeric Antibody (HACA).
Patients receiving any medications or substances that are strong inhibitors or inducers of Cytochrome P450, family 3, subfamily A (CYP3A) enzyme are ineligible.
Uncontrolled intercurrent illness.
Prisoners.
Pregnant or breast-feeding women.
Known Human Immunodeficiency Virus (HIV) or active Hepatitis B infection
Any prior or active cancer, which in the opinion of the investigator would preclude safe participation in this study.